Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Asparaginases: biochemical pharmacology and modes of drug resistance.

Avramis VI.

Anticancer Res. 2012 Jul;32(7):2423-37. Review.

PMID:
22753699
2.

Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines.

Su N, Pan YX, Zhou M, Harvey RC, Hunger SP, Kilberg MS.

Pediatr Blood Cancer. 2008 Feb;50(2):274-9.

PMID:
17514734
3.

Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961).

Panosyan EH, Grigoryan RS, Avramis IA, Seibel NL, Gaynon PS, Siegel SE, Fingert HJ, Avramis VI.

Anticancer Res. 2004 Mar-Apr;24(2C):1121-5.

4.

Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961).

Grigoryan RS, Panosyan EH, Seibel NL, Gaynon PS, Avramis IA, Avramis VI.

In Vivo. 2004 Mar-Apr;18(2):107-12.

5.

In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase.

Asselin BL, Ryan D, Frantz CN, Bernal SD, Leavitt P, Sallan SE, Cohen HJ.

Cancer Res. 1989 Aug 1;49(15):4363-8.

7.

Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia.

Raetz EA, Salzer WL.

J Pediatr Hematol Oncol. 2010 Oct;32(7):554-63. doi: 10.1097/MPH.0b013e3181e6f003. Review.

PMID:
20724951
8.
9.

The combination regimen of idarubicin and taxotere is effective against human drug-resistant leukemic cell lines.

Majlessipour F, Avramis IA, Kwock R, Weinberg KI, Avrami VI.

Anticancer Res. 2002 May-Jun;22(3):1361-8.

PMID:
12168812
10.

Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy.

Li YT, Kwon YM, Spangrude GJ, Liang JF, Chung HS, Park YJ, Yang VC.

J Biomed Mater Res A. 2009 Oct;91(1):209-20. doi: 10.1002/jbm.a.32204.

PMID:
18814276
13.

Use of L-asparaginase in childhood ALL.

Müller HJ, Boos J.

Crit Rev Oncol Hematol. 1998 Aug;28(2):97-113. Review.

PMID:
9768345
14.

L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment.

Tsurusawa M, Chin M, Iwai A, Nomura K, Maeba H, Taga T, Higa T, Kuno T, Hori T, Muto A, Yamagata M; Japanese Children's Cancer and Leukemia Study Group..

Cancer Chemother Pharmacol. 2004 Mar;53(3):204-8. Epub 2003 Nov 22.

PMID:
14634792
15.
16.
17.

Development of a double-drug-resistant human leukemia model to cytosine arabinoside and L-asparaginase: evaluation of cross-resistance to other treatment modalities.

Majlessipour F, Kwock R, Martin-Aragon S, Weinberg KI, Avramis VI.

Anticancer Res. 2001 Jan-Feb;21(1A):11-22.

PMID:
11299723
18.

Five-year single-center study of asparaginase therapy within the ALL-BFM 2000 trial.

Schrey D, Speitel K, Lanvers-Kaminsky C, Gerss J, Möricke A, Boos J.

Pediatr Blood Cancer. 2011 Sep;57(3):378-84. doi: 10.1002/pbc.23041. Epub 2011 Feb 18.

PMID:
21337682
19.

Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system.

Albertsen BK, Schrøder H, Ingerslev J, Jakobsen P, Avramis VI, Müller HJ, Carlsen NT, Schmiegelow K.

Br J Haematol. 2001 Dec;115(4):983-90.

PMID:
11843837
20.

A clinically attainable dose of L-asparaginase targets glutamine addiction in lymphoid cell lines.

Sugimoto K, Suzuki HI, Fujimura T, Ono A, Kaga N, Isobe Y, Sasaki M, Taka H, Miyazono K, Komatsu N.

Cancer Sci. 2015 Nov;106(11):1534-43. doi: 10.1111/cas.12807. Epub 2015 Oct 16.

Supplemental Content

Support Center